Exelixis (NASDAQ:EXEL) has climbed 2.98% in the past week and advanced 36.69% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.22% and the outperformance has advanced to 35.44% for the last 4 weeks period.
Exelixis (NASDAQ:EXEL): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.57 and $7.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.60, notching a gain of 0.66% for the day. The total traded volume was 11,624,644 . The stock had closed at $7.55 on the previous day.
The company shares have rallied 93.38% from its 1 Year high price. On Jun 17, 2016, the shares registered one year high at $7.75 and the one year low was seen on Jul 6, 2015. The 50-Day Moving Average price is $6.05 and the 200 Day Moving Average price is recorded at $4.87.
On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Exelixis, Inc., Willsey Lance had purchased shares worth of $297,600 in a transaction dated on May 9, 2016. A total of 60,000 shares were purchased at a price of $4.96 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Stifel Nicolaus upgrades their rating on the shares of Exelixis (NASDAQ:EXEL). The current rating of the shares is Buy. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on April 4, 2016. Currently the company Insiders own 5.9% of Exelixis shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 11.81% . Institutional Investors own 77.15% of Exelixis shares. During last six month period, the net percent change held by insiders has seen a change of 11.81%.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).